Aims Previous evidence has demonstrated that participation in the Dose Adjustment for Normal Eating (DAFNE) education programme can reduce HbA 1c and severe hypoglycaemia in people with Type 1 diabetes. In a number of studies, increased HbA 1c variability has been associated with higher diabetic morbidity and mortality. No studies have examined the impact of structured education on HbA 1c variability in Type 1 diabetes.
Introduction
The Diabetes Control and Complications Study (DCCT) demonstrated that tight glycaemic control as measured by HbA 1c reduced microvascular complications in people with Type 1 diabetes [1] . Current guidelines for the management of adults with Type 1 diabetes advocate structured training in insulin dose adjustment skills to support the person with diabetes in achieving tight glycaemic targets [2, 3] . In the UK, the national Dose Adjustment for Normal Eating (DAFNE) programme, derived from the German Diabetes Teaching and Treatment Programme (DTTP), provides an evidencebased training course for adults with Type 1 diabetes. Participation in DAFNE can reduce HbA 1c and is cost effective [4] [5] [6] . There are psychosocial benefits, and significant reductions in severe hypoglycaemia and diabetic ketoacidosis [7, 8] .
HbA 1c is an important measure of medium-term average glucose exposure, but it is not the only measure of glycaemic control. Glucose variability has been consistently shown to be associated with increased risk of both morbidity and mortality in diabetes [9] [10] [11] [12] . Glucose variability has previously been defined in multiple ways. Usually it is taken as the between-minute or between-hour changes in continuous glucose monitoring (CGM) or capillary blood glucose (CBG) measurements, which are used in real time to make decisions about insulin dose or carbohydrate intake [13] . Glucose variability has also been used to describe variations in glucose measurements between day or weeks [14] .
An important measure of long-term, month-to-month, glucose variability is the fluctuation between HbA 1c measurements. When describing HbA 1c variability, studies have used either the standard deviation (SD) or coefficient of variation (CV). Both SD and CV are measures of variability. The SD measures how much values differ from the group mean, whereas CV is the ratio of SD to the mean. There is no agreed standardized method of expressing HbA 1c variability [10] .
In Type 2 diabetes greater HbA 1c variability has been consistently associated with microvascular complications and has been linked with increased frequency of cardiovascular events and all-cause mortality, independent of baseline HbA 1c [10, [14] [15] [16] [17] .
In Type 1 diabetes, the DCCT did not uncover an association between short-term glucose variability and increased risk of microvascular complications, as measured via SD [18, 19] . By contrast, longer term HbA 1c variability in Type 1 diabetes, also measured via SD, was shown to predict development of retinopathy and nephropathy over and above the mean HbA 1c value [19, 20] . The DCCT used 3-monthly seven-point glucose profiles equivalent to 28 finger-stick measurements per year, which may not have been enough data to adequately assess glucose variability. An increased incidence of cardiovascular events has also been associated with increased HbA 1c variability in Type 1 diabetes, with the magnitude of the impact proposed to be at least as high as that of mean HbA 1c [20, 21] . In people with Type 1 diabetes, greater HbA 1c variability as measured by CV has also been shown to be associated with earlier hospital admission and increased all-cause mortality [22] .
Because there is a potential positive impact of reducing HbA 1c variability in people with Type 1 diabetes, we aimed to investigate the effect of participating in a DAFNE course on subsequent HbA 1c variability.
Methods

Study description
An observational study was performed. Individuals coded with a diagnosis of Type 1 diabetes within SCI-Diabetes (a database containing data of all people known to have diabetes living in Scotland), who had attended a DAFNE education course within NHS Greater Glasgow and Clyde between 19 November 2007 and 21 September 2015 were eligible for inclusion. If more than one DAFNE course had been attended, the first was taken as the index course for analysis.
Exclusion criteria were a diagnosis of Type 1 diabetes within 18 months of the DAFNE course (to avoid including people with persisting endogenous insulin production), use of continuous subcutaneous insulin infusion (CSII) therapy and pregnancy. HbA 1c data from individuals who commenced CSII therapy post-DAFNE were included in the analysis up to the point of CSII initiation. Similarly, data from those who became pregnant during the follow-up period were included up to the start of pregnancy.
Analysis of impact of DAFNE on HbA 1c levels
The median of all HbA 1c measures made in the 12 months prior to the DAFNE course was taken as the pre-course level. Follow-up time points of 12, 24, 36, 48 and 60 months were chosen. A separate analysis was performed at each time point, comparing post-course HbA 1c with pre-course HbA 1c for those for whom there was an adequate follow-up interval. At each time point, all HbA 1c values for each individual within a window of plus or minus half of the interval between time points were identified (e.g. at 12 months, all measurements between 6 and 18 months were identified). The closest HbA 1c value to the time point within this window was taken to represent the HbA 1c at this point of follow-up.
At each follow-up time point, individuals with missing data were identified. Missing data were defined as no available HbA 1c within the follow-up window around the time point of interest, where the individual had not started on pump therapy, become pregnant or died, and for whom the DAFNE course had not been attended too recently for a follow-up measure at the appropriate time. For these individuals, an HbA 1c value equal to the pre-course HbA 1c was imputed, to mitigate the possibility that those with poor outcome attended less frequently for follow-up.
At each time point, HbA 1c values were compared with precourse HbA 1c values using a paired Mann-Whitney U test. Difference in median HbA 1c was calculated.
Analysis of impact of DAFNE on HbA1c variability
A maximum window of 5 years pre-and 5 years post-DAFNE course was taken and HbA 1c measurements within this window were identified. Individuals using CSII or with a recorded pregnancy during this analysis window were not included. The time differences between the course start date and both the first pre-course HbA 1c , and the last post-course HbA 1c measurement were calculated. HbA 1c values from an equal period pre-and post-course were analysed. Given the strong association between a higher testing frequency and greater variability, the number of tests pre-and post-course was equalized with individual by matching the number of HbA 1c values within the periods of interest pre-and postcourse. Matching to achieve an equal number of HbA 1c values pre-and post-DAFNE was performed by removal of What's new?
• HbA 1c variability is known to be associated with mortality in people with Type 1 diabetes.
• Structured education (DAFNE) attendance is associated with a reduction in HbA 1c variability.
• Reduced HbA 1c variability following structured education may potentially be beneficial in people with Type 1 diabetes.
randomly selected HbA 1c values from the period containing the greater number of measurements. A random number between 0 and 1 was assigned to each measurement using the R function runif() (uniform distribution random number generator). Values were ordered by this random number, and the first n values were taken, where n is the number of values in the period with the fewer measurements. The number of measurements ranged from 3 to 6 for the sample considered.
Mean, SD and CV of HbA 1c values for each individual were calculated pre-and post-course. Pre-and post-course metrics were compared using a Wilcoxon signed-rank test.
Results
Some 1061 individuals underwent DAFNE education and 687 met the inclusion criteria (406 female). Some 628 were identified as white European, five South Asian, one Chinese and one African. The remainder (52) did not have an identified ethnic status within the dataset. Median [interquartile range (IQR)] age at the time of the course was 37.1 (28.4-48.8) years, with a median (IQR) time from diagnosis to DAFNE course of 16.1 (8.9-24.3) years.
Impact of DAFNE on HbA 1c
The numbers of individuals with HbA 1c values from each time point of interest (12-60 months) are shown in Table 1 . Maximal significant median reduction in HbA 1c (À3.5 mmol/mol) was seen at 12 months, with a significant median reduction (À1.5 mmol/mol) at 60 months of follow-up.
Impact of DAFNE on HbA 1c variability
Median matched window pre-and post-DAFNE course was 3.49 (IQR 2.10-4.40) years, with 4 (3-6) HbA 1c measurements analysed during each period (Table 2 ). Mean and SD HbA 1c were significantly lower during the post-DAFNE period, with a significant reduction in CV post DAFNE.
Conclusion
Our data confirmed a reduction in median HbA 1c post DAFNE course that is sustained for up to 5 years, in line with previous published reports [4, 23] . The effect diminished with time, possibly due to people reverting to pre-course behaviours. This study included all participants in DAFNE regardless of their reason for attending the course. The overall benefit of DAFNE may be underestimated for several reasons. People attending a course because of recurrent severe hypoglycaemia may have a low HbA 1c at baseline, and we excluded the newly diagnosed group to avoid including those who may be experiencing a 'honeymoon period'. Furthermore, we imputed baseline HbA 1c where follow-up data are missing, pump therapy, become pregnant or died, and for whom the DAFNE course had not been attended too recently for a follow-up measure at the appropriate time.
ª 2018 Diabetes UK to minimize the possibility of overstating benefit from DAFNE due to missing data. Our data show that when adjusted to match for number of tests performed, HbA 1c variability as measured by CV decreases significantly after DAFNE participation. There is no accepted standard measure of variability of HbA 1c . We suggest that the use CV is most appropriate as this measure is calculated using both mean and SD. CV therefore intrinsically mitigates the influence of mean HbA 1c on variability.
The potential mechanisms of the observed reduction in variability are uncertain. It is possible that HbA 1c variability could be a marker of variable treatment concordance because people with greater variability may be more intermittently engaged with intensive insulin therapy. Completion of DAFNE affords people with diabetes a more in-depth understanding of their disease and skills for better glucose management during life events or changes in daily routine. DAFNE attendance is also known to improve indices of quality of life and increase feelings of control and empowerment [4, [24] [25] [26] . DAFNE training may therefore equip people with a greater resilience to life events, which is then reflected in their ability to maintain HbA 1c levels consistently.
The strength of our study is that it is an analysis of an inclusive database of a large number of people with Type 1 diabetes. Some 6244 people with Type 1 diabetes were registered on the SCI database in Greater Glasgow and Clyde in 2015 at the end of our study period. Exclusion of data from people after initiation of CSII therapy and if a pregnancy occurred also reduces the possibility of bias. The study is limited in that is retrospective with a relatively short follow-up period of a patients who were deemed appropriate for, and willing to engage with, a 5-day DAFNE course. Another possible confounding factor is that 15% of patient follow-up data were not available at 45 months. It is possible that people were more likely to be lost to follow-up if they have poor glycaemic control and a chaotic lifestyle. To adjust for this possibility the data have been analysed with the assumption that all people without follow-up data did not have an improvement in HbA 1c and post-course HbA 1c was imputed as being the same as pre-course HbA 1c .
This is the first study to demonstrate a relationship between completion of structured education and a reduction in HbA 1c variability in people with Type 1 diabetes. Our results may have clinical implications in that it provides further evidence of the beneficial effect of structured education in general and DAFNE in particular. The reduction in HbA 1c variability demonstrated in this study could potentially reduce the increased mortality associated with higher HbA 1c variability described in people with Type 1 diabetes [22] . This further supports the view that structured education should be made available to all people with Type 1 diabetes and be strongly promoted.
In conclusion, we found that participation in the structured education programme DAFNE led to a sustained reduction in median HbA 1c and a reduction in HbA 1c variability. This evidence gives further support for the beneficial impact of DAFNE for people with Type 1 diabetes.
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